•  
  •  
  •  
  •  

2026-05-31 18:13:05

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • XTGlobal Infotech Limited Delivers Stellar Performance with ~39% Jump in PAT YoY
  • Mini Diamonds India Ltd announces Launch of Fancy Coloured LabGrown Diamond Jewellery Line through Namra Jewels Pvt Ltd
  • Gaudium IVF Delivers Record Q4FY26: Revenue, EBITDA and PAT
  • Unimech Aerospace and Manufacturing Ltd delivers strong Q4 FY26 Performance
  • EFC India Ltd reports strong results powering next phase of growth

Keywords Selected:  Tide

Stock Report

  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes
  • Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) In India
  • Eris Lifesciences Ltd to launch Weekly Shot of Semaglutide Starting at ₹220 Per Shot
  • Biocon obtains approval for weight management drug, Liraglutide, in the United States
  • Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India
  • OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic® in Saudi Arabia
  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
  • Biocon Limited launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
  • Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
  • Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes
  • Lilly and Cipla sign a distribution and promotion agreement for Yurpeak® in India
  • Lupin Launches Liraglutide Injection in the United States
  • Lupin receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
  • Biocon Limited launches its Glucagon-like peptide-1 (GLP -1), Liraglutide, in the United Kingdom
  • Biocon Ltd signs semi-exclusive distribution and supply deal for the commercialization of generic Saxenda® in Mexico with Medix
  • Nitta Gelatin launches Expansion Project
  • Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide
  • Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.
  • Glenmark is the first to launch Biosimilar of Popular Anti‐Diabetic Drug, Liraglutide, in India
  • Tide and Transcorp launch India's-first recycled PVC RuPay Card
  • Biocon Limited enters into a commercialization agreement with Zentiva in Europe

Latest Post

  • XTGlobal Infotech Limited Delivers Stellar Performance with ~39% Jump in PAT YoY
  • Mini Diamonds India Ltd announces Launch of Fancy Coloured LabGrown Diamond Jewellery Line through Namra Jewels Pvt Ltd
  • Gaudium IVF Delivers Record Q4FY26: Revenue, EBITDA and PAT
  • Unimech Aerospace and Manufacturing Ltd delivers strong Q4 FY26 Performance
  • EFC India Ltd reports strong results powering next phase of growth


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025